No-Spa (Drotaverine Hydrochloride)

Drotaverine hydrochloride inhibits phosphodiesterase enzymes, which raises intracellular cyclic AMP levels. The increased cAMP leads to smooth‑muscle relaxation. Additionally, the drug exhibits calcium‑antagonist activity, further decreasing calcium‑mediated contraction, which together help alleviate spasms in the gastrointestinal, biliary, renal and uterine tissues.

The appropriate dose of No‑Spa is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for drotaverine hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order No‑Spa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with other antispasmodics such as hyoscine or papaverine, drotaverine offers a non‑anticholinergic mechanism, reducing the likelihood of dry‑mouth and blurred vision. Its dual phosphodiesterase inhibition and calcium‑antagonist activity provide effective smooth‑muscle relaxation with a generally favorable tolerability profile.

No‑Spa should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, excessive heat and direct sunlight to maintain product stability.

No‑Spa is administered orally, typically as a tablet that is swallowed with water. The exact administration schedule, including timing relative to meals, should follow the prescribing clinician’s directions.

Serious but rare risks include significant hypotension, allergic reactions such as rash or urticaria, cardiac arrhythmias, and hepatic dysfunction. Patients should seek immediate medical attention if they experience symptoms like severe dizziness, chest pain, or signs of an allergic reaction.

No‑Spa should be avoided in individuals with known hypersensitivity to drotaverine or any excipients, in patients with severe cardiovascular instability, uncontrolled hypertension, or significant liver disease unless specifically advised by a physician.